Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer

Background: Recent dose-intensity studies of small-cell lung cancer (SCLC) have yielded conflicting results. We carried out a phase III randomized trial in patients with better-prognosis SCLC (i.e., prognostic score of 0–1) to investigate whether doubling the dose density of ifosfamide, carboplatin,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2005-05, Vol.97 (9), p.666-674
Hauptverfasser:	Lorigan, Paul, Woll, Penella J., O'Brien, M. E. R., Ashcroft, Linda F., Sampson, Mark R., Thatcher, Nick
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Carboplatin - administration & dosage Carboplatin - adverse effects Carcinoma, Small Cell - drug therapy Chemotherapy Clinical trials Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Comparative analysis Dose-Response Relationship, Drug Drug Administration Schedule Etoposide - administration & dosage Etoposide - adverse effects Female Filgrastim Granulocyte Colony-Stimulating Factor - therapeutic use Hematopoietic Stem Cells Humans Ifosfamide - administration & dosage Ifosfamide - adverse effects Incidence Lung cancer Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Neutropenia - chemically induced Neutropenia - prevention & control Oncology Pharmacology. Drug treatments Prognosis Recombinant Proteins Severity of Illness Index Survival Analysis Toxicity Transplantation, Autologous Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!